Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes

References

• Ramazzotti G, Faenza I, Fiume R, et al. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol. 2011;226(1):14–20.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Fiume R, Faenza I, et al. Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction. Histol Histopathol. 2005;20(4):1251–1260.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Follo MY, Evangelisti C, et al. Nuclear inositol lipid metabolism: more than just second messenger generation? J Cell Biochem. 2005 Oct 1;96(2):285–292.
   PubMed Web of Science ®Google Scholar
• Follo MY, Manzoli L, Poli A, et al. PLC and PI3K/Akt/mTOR signalling in disease and cancer. Adv Biol Regul. 2015 Jan;57:10–16.
   PubMedGoogle Scholar
• Keune WJ, Jones DR, Divecha N. PtdIns5P and Pin1 in oxidative stress signaling. Adv Biol Regul. 2013 May;53(2):179–189.
   PubMedGoogle Scholar
• Yang YR, Follo MY, Cocco L, et al. The physiological roles of primary phospholipase C. Adv Biol Regul. 2013;53(3):232–241.
   PubMedGoogle Scholar
• Cocco L, Gilmour RS, Ognibene A, et al. Synthesis of polyphosphoinositides in nuclei of Friend cells. Evidence for polyphosphoinositide metabolism inside the nucleus which changes with cell differentiation. Biochem J. 1987 Dec 15;248(3):765–770.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Gilmour RS, Bertagnolo V, et al. Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. Nature. 1992 Jul 16;358(6383):242–245.
   PubMed Web of Science ®Google Scholar
• Ramazzotti G, Faenza I, Follo MY, et al. Nuclear phospholipase C in biological control and cancer. Crit Rev Eukaryot Gene Expr. 2011;21(3):291–301.
   PubMed Web of Science ®Google Scholar
• Shah ZH, Jones DR, Sommer L, et al. Nuclear phosphoinositides and their impact on nuclear functions. Febs J. 2013;280(24):6295–6310.
   PubMed Web of Science ®Google Scholar
• Faenza I, Billi AM, Follo MY, et al. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Anticancer Res. 2005;25(3B):2039–2041.
   PubMed Web of Science ®Google Scholar
• Follo MY, Faenza I, Piazzi M, et al. Nuclear PI-PLCbeta1: an appraisal on targets and pathology. Adv Biol Regul. 2014 Jan;54:2–11.
   PubMedGoogle Scholar
• Poli A, Mongiorgi S, Cocco L, et al. Protein kinase C involvement in cell cycle modulation. Biochem Soc Trans. 2014;42(5):1471–1476.
   PubMed Web of Science ®Google Scholar
• Matkovic K, Brugnoli F, Bertagnolo V, et al. The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia. 2006;20(6):941–951.
   PubMed Web of Science ®Google Scholar
• Ciechomska I, Pyrzynska B, Kazmierczak P, et al. Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene. 2003 Oct 23;22(48):7617–7627.
   PubMed Web of Science ®Google Scholar
• Cocco L, Follo MY, Manzoli L, et al. Phosphoinositide-specific phospholipase C in health and disease. J Lipid Res. 2015;56(10):1853–1860.
   PubMed Web of Science ®Google Scholar
• Rhee SG. Reflections on the days of phospholipase C. Adv Biol Regul. 2013 Sep;53(3):223–231.
   PubMedGoogle Scholar
• Suh PG, Park JI, Manzoli L, et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep. 2008 Jun 30;41(6):415–434.
   PubMed Web of Science ®Google Scholar
• Cocco L, Follo MY, Faenza I, et al. Physiology and pathology of nuclear phospholipase C beta1. Adv Enzyme Regul. 2011;51(1):2–12.
   PubMedGoogle Scholar
• Follo MY, Faenza I, Fiume R, et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Biol Regul. 2012;52(1):2–6.
   PubMedGoogle Scholar
• Follo MY, Marmiroli S, Faenza I, et al. Nuclear phospholipase C beta1 signaling, epigenetics and treatments in MDS. Adv Biol Regul. 2013;53(1):2–7.
   PubMedGoogle Scholar
• Garcia Del Cano G, Montana M, Aretxabala X, et al. Nuclear phospholipase C-beta1 and diacylglycerol LIPASE-alpha in brain cortical neurons. Adv Biol Regul. 2014 Jan;54:12–23.
   PubMedGoogle Scholar
• Ross CA, MacCumber MW, Glatt CE, et al. Brain phospholipase C isozymes: differential mRNA localizations by in situ hybridization. Proc Natl Acad Sci U S A. 1989;86(8):2923–2927.
   PubMed Web of Science ®Google Scholar
• Yamakawa A, Nishizawa M, Fujiwara KT, et al. Molecular cloning and sequencing of cDNA encoding the phosphatidylinositol kinase from rat brain. J Biol Chem. 1991 Sep 15;266(26):17580–17583.
   PubMed Web of Science ®Google Scholar
• Hannan AJ, Kind PC, Blakemore C. Phospholipase C-beta1 expression correlates with neuronal differentiation and synaptic plasticity in rat somatosensory cortex. Neuropharmacology. 1998 Apr-May;37(45):593–605.
   PubMed Web of Science ®Google Scholar
• Spires TL, Molnar Z, Kind PC, et al. Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. Cereb Cortex. 2005;15(4):385–393.
   PubMed Web of Science ®Google Scholar
• Choi WC, Gerfen CR, Suh PG, et al. Immunohistochemical localization of a brain isozyme of phospholipase C (PLC III) in astroglia in rat brain. Brain Res. 1989 Oct 9;499(1):193–197.
   PubMed Web of Science ®Google Scholar
• Kim D, Jun KS, Lee SB, et al. Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature. 1997 Sep 18;389(6648):290–293.
   PubMed Web of Science ®Google Scholar
• Kurian MA, Meyer E, Vassallo G, et al. Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. Brain. 2010 Oct;133(10):2964–2970.
   PubMed Web of Science ®Google Scholar
• Poduri A, Chopra SS, Neilan EG, et al. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012 Aug;53(8):e146–e150.
   Web of Science ®Google Scholar
• Lo Vasco VR, Cardinale G, Polonia P. Deletion of PLCB1 gene in schizophrenia-affected patients. J Cell Mol Med. 2012 Apr;16(4):844–851.
   PubMed Web of Science ®Google Scholar
• Lo Vasco VR, Longo L, Polonia P. Phosphoinositide-specific phospholipase C beta1 gene deletion in bipolar disorder affected patient. J Cell Commun Signal. 2013 Mar;7(1):25–29.
   PubMed Web of Science ®Google Scholar
• Faenza I, Ramazzotti G, Bavelloni A, et al. Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology. 2007;148(3):1108–1117.
   PubMed Web of Science ®Google Scholar
• O’Carroll SJ, Mitchell MD, Faenza I, et al. Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. Cell Signal. 2009;21(6):926–935.
   PubMed Web of Science ®Google Scholar
• Follo MY, Russo D, Finelli C, et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia. 2012;26(5):943–950.
   PubMed Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Clissa C, et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia. 2012;26(12):2474–2482.
   PubMed Web of Science ®Google Scholar
• Cocco L, Follo MY, Faenza I, et al. Inositide signaling in the nucleus: from physiology to pathology. Adv Enzyme Regul. 2010;50(1):2–11.
   PubMedGoogle Scholar
• Manzoli L, Mongiorgi S, Clissa C, et al. Strategic role of nuclear inositide signalling in myelodysplastic syndromes therapy. Mini Rev Med Chem. 2014;14(11):873–883.
   Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Finelli C, et al. Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem. 2010 Apr 15;109(6):1065–1071.
   PubMed Web of Science ®Google Scholar
• Yang YR, Choi JH, Chang JS, et al. Diverse cellular and physiological roles of phospholipase C-gamma1. Adv Biol Regul. 2012;52(1):138–151.
   PubMedGoogle Scholar
• Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013 Jan;14(1):7–23.
   PubMed Web of Science ®Google Scholar
• Lucas G, Hendolin P, Harkany T, et al. Neurotrophin-4 mediated TrkB activation reinforces morphine-induced analgesia. Nat Neurosci. 2003;6(3):221–222.
   PubMed Web of Science ®Google Scholar
• Jang HJ, Yang YR, Kim JK, et al. Phospholipase C-gamma1 involved in brain disorders. Adv Biol Regul. 2013;53(1):51–62.
   PubMedGoogle Scholar
• Manzoli L, Martelli AM, Billi AM, et al. Nuclear phospholipase C: involvement in signal transduction. Prog Lipid Res. 2005;44(4):185–206.
   PubMed Web of Science ®Google Scholar
• Koss H, Bunney TD, Behjati S, et al. Dysfunction of phospholipase Cgamma in immune disorders and cancer. Trends Biochem Sci. 2014;39(12):603–611.
   PubMed Web of Science ®Google Scholar
• Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46(4):376–379.
   PubMed Web of Science ®Google Scholar
• Kunze K, Spieker T, Gamerdinger U, et al. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Cancer Res. 2014 Nov 1;74(21):6173–6183.
   PubMed Web of Science ®Google Scholar
• Raimondi C, Falasca M. Phosphoinositides signalling in cancer: focus on PI3K and PLC. Adv Biol Regul. 2012 Jan;52(1):166–182.
   PubMedGoogle Scholar
• Lattanzio R, Piantelli M, Falasca M. Role of phospholipase C in cell invasion and metastasis. Adv Biol Regul. 2013 Sep;53(3):309–318.
   PubMedGoogle Scholar
• Yang J, Song X, Chen Y, et al. PLCgamma1-PKCgamma signaling-mediated Hsp90alpha plasma membrane translocation facilitates tumor metastasis. Traffic. 2014;15(8):861–878.
   PubMed Web of Science ®Google Scholar
• Choi JH, Yang YR, Lee SK, et al. Phospholipase C-gamma1 potentiates integrin-dependent cell spreading and migration through Pyk2/paxillin activation. Cell Signal. 2007;19(8):1784–1796.
   PubMed Web of Science ®Google Scholar
• Xie Z, Peng J, Pennypacker SD, et al. Critical role for the catalytic activity of phospholipase C-gamma1 in epidermal growth factor-induced cell migration. Biochem Biophys Res Commun. 2010 Aug 27;399(3):425–428.
   PubMed Web of Science ®Google Scholar
• Davies G, Martin TA, Ye L, et al. Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol. 2008;26(4):386–391.
   PubMed Web of Science ®Google Scholar
• Satake A, Schmidt AM, Archambault A, et al. Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells. J Autoimmun. 2013 Aug;44:13–20.
   PubMed Web of Science ®Google Scholar
• Ebinu JO, Stang SL, Teixeira C, et al. RasGRP links T-cell receptor signaling to Ras. Blood. 2000 May 15;95(10):3199–3203.
   PubMed Web of Science ®Google Scholar
• Vaque JP, Gomez-Lopez G, Monsalvez V, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014 Mar 27;123(13):2034–2043.
   PubMed Web of Science ®Google Scholar
• Liao HJ, Kume T, McKay C, et al. Absence of erythrogenesis and vasculogenesis in Plcg1- deficient mice. J Biol Chem. 2002 Mar 15;277(11):9335–9341.
   PubMed Web of Science ®Google Scholar
• Jing CB, Chen Y, Dong M, et al. Phospholipase C gamma-1 is required for granulocyte maturation in zebrafish. Dev Biol. 2013 Feb 1;374(1):24–31.
   PubMed Web of Science ®Google Scholar
• Alimandi M, Heidaran MA, Gutkind JS, et al. PLC-gamma activation is required for PDGF-betaR-mediated mitogenesis and monocytic differentiation of myeloid progenitor cells. Oncogene. 1997 Jul 31;15(5):585–593.
   PubMed Web of Science ®Google Scholar
• Rameh LE, Rhee SG, Spokes K, et al. Phosphoinositide 3-kinase regulates phospholipase Cgamma-mediated calcium signaling. J Biol Chem. 1998 Sep 11;273(37):23750–23757.
   PubMed Web of Science ®Google Scholar
• Kriplani N, Hermida MA, Brown ER, et al. Class I PI 3-kinases: function and evolution. Adv Biol Regul. 2015 Sep;59:53–64.
   PubMedGoogle Scholar
• Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul. 2014 May;55:28–38.
   PubMedGoogle Scholar
• McCubrey JA, Davis NM, Abrams SL, et al. Targeting breast cancer initiating cells: advances in breast cancer research and therapy. Adv Biol Regul. 2014 Sep;56:81–107.
   PubMedGoogle Scholar
• McCubrey JA, Abrams SL, Fitzgerald TL, et al. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Adv Biol Regul. 2015 Jan;57:75–101.
   PubMedGoogle Scholar
• Martelli AM, Evangelisti C, Follo MY, et al. Targeting the phosphatidylinositol 3- kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem. 2011;18(18):2715–2726.
   PubMed Web of Science ®Google Scholar
• Liu P, Gan W, Chin YR, et al. PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 2015;5(11):1194–1209.
   PubMed Web of Science ®Google Scholar
• Yang G, Murashige DS, Humphrey SJ, et al. A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation. Cell Rep. 2015 Aug 11;12(6):937–943.
   PubMed Web of Science ®Google Scholar
• Jhanwar-Uniyal M, Jeevan D, Neil J, et al. Deconstructing mTOR complexes in regulation of glioblastoma multiforme and its stem cells. Adv Biol Regul. 2013;53(2):202–210.
   PubMedGoogle Scholar
• Boultwood J, Yip BH, Vuppusetty C, et al. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. Adv Biol Regul. 2013;53(1):8–17.
   PubMedGoogle Scholar
• Wong PM, Feng Y, Wang J, et al. Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A. Nat Commun. 2015 Aug 27;6:8048.
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC, et al. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets. 2012;16(12):1203–1214.
   PubMed Web of Science ®Google Scholar
• Guida M, Maraldi T, Beretti F, et al. Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromes. Biomed Res Int. 2014;2014( Article ID 456937):1–11.
   Web of Science ®Google Scholar
• Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther. 2015;3(2):1–17.
   PubMedGoogle Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
   PubMed Web of Science ®Google Scholar
• Jhanwar SC. Genetic and epigenetic pathways in myelodysplastic syndromes: a brief overview. Adv Biol Regul. 2015 May;58:28–37.
   PubMedGoogle Scholar
• Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7(2):118–129.
   PubMed Web of Science ®Google Scholar
• Elias HK, Schinke C, Bhattacharyya S, et al. Stem cell origin of myelodysplastic syndromes. Oncogene. 2014 Oct 30;33(44):5139–5150.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Sep;90(9):831–841.
   PubMed Web of Science ®Google Scholar
• Mongiorgi S, Follo MY, Clissa C, et al. Nuclear PI-PLC beta1 and myelodysplastic syndromes: from bench to clinics. Curr Top Microbiol Immunol. 2012;362:235–245.
   PubMed Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Finelli C, et al. Nuclear PI-PLCbeta1 and myelodysplastic syndromes: genetics and epigenetics. Curr Pharm Des. 2012;18(13):1751–1754.
   PubMed Web of Science ®Google Scholar
• Follo MY, Bosi C, Finelli C, et al. Real-time PCR as a tool for quantitative analysis of PI- PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med. 2006;18(2):267–271.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Clissa C, et al. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol. 2009 Feb 10;27(5):782–790.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811–16816.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Mongiorgi S, et al. Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia. 2011 Feb;25(2):271–280.
   PubMed Web of Science ®Google Scholar
• Cocco L, Finelli C, Mongiorgi S, et al. An increased expression of PI-PLCbeta1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. J Leukoc Biol. 2015 Nov 15;98(5):769–780.
   PubMed Web of Science ®Google Scholar
• Fili C, Malagola M, Follo MY, et al. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res. 2013 Jun 15;19(12):3297–3308.
   PubMed Web of Science ®Google Scholar
• Ingley E. Integrating novel signaling pathways involved in erythropoiesis. IUBMB Life. 2012 May;64(5):402–410.
   PubMed Web of Science ®Google Scholar
• Schnoder TM, Arreba-Tutusaus P, Griehl I, et al. Epo-induced erythroid maturation is dependent on Plcgamma1 signaling. Cell Death Differ. 2015;22(6):974–985.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Bosi C, et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia. 2008;22(1):198–200.
   PubMed Web of Science ®Google Scholar
• Nyakern M, Tazzari PL, Finelli C, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia. 2006;20(2):230–238.
   PubMed Web of Science ®Google Scholar
• Follo MY, Mongiorgi S, Bosi C, et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res. 2007 May 1;67(9):4287–4294.
   PubMed Web of Science ®Google Scholar
• Mahajan K, Mahajan NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol. 2012 Sep;227(9):3178–3184.
   PubMed Web of Science ®Google Scholar
• Walter RB. The role of CD33 as therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets. 2014 Jul;18(7):715–718.
   PubMed Web of Science ®Google Scholar
• Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015 Jan;19(1):37–54.
   PubMed Web of Science ®Google Scholar
• Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793–2803.
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D’Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17–S27.
   PubMed Web of Science ®Google Scholar
• Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013 May;17(5):507–531.
   PubMed Web of Science ®Google Scholar
• Pettersson F, Del Rincon SV, Miller WH Jr. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. Expert Opin Ther Targets. 2014 Sep;18(9):1035–1048.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Reikvam H. Therapeutic targeting of NF-kappaB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity. Expert Opin Ther Targets. 2010 Nov;14(11):1139–1142.
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets. 2010 Nov;14(11):1157–1176.
   PubMed Web of Science ®Google Scholar